Natera acquired Foresight Diagnostics for $275 million upfront plus up to $175 million in milestones to integrate high-sensitivity phased-variant ctDNA technology into its Signatera minimal residual disease (MRD) platform. Foresight’s PhasED-Seq approach detects phased variants to improve sensitivity and is already being used in lymphoma-focused research and trials. Natera said the purchase immediately enhances its MRD capabilities—lifting sensitivity for solid tumors and enabling expansion into lymphoma markets—while combining commercial infrastructure and trial pipelines. The enhanced Signatera product will be available for research use now and for clinical launch in 2026, according to the company. The deal signals ongoing consolidation in the precision-oncology diagnostics market and underscores MRD’s role as a clinical decision tool for adjuvant therapy and trial enrichment. Pharma partners running investigational studies and health systems planning MRD adoption should expect capability upgrades and potential new reimbursement discussions tied to improved detection performance.